While recuperating from my shoulder replacement (and after signing the usual stack of preoperative forms absolving the surgeon, the hospital, the anesthesiologist, and possibly the parking attendant of every imaginable complication, including dying on the table), I had a lot of time to watch television. Daytime television. The kind with a steady rotation of direct-to-consumer pharmaceutical ads.

If you ever want to understand the state of American medicine, don’t read policy papers. Watch what comes on between the weather and the local car dealership commercial.

The pattern is always the same. The condition is mild, almost quaint: Mild eczema. A little bloating. A touch of seasonal melancholy.

Then the voiceover pivots into a pharmacologic apocalypse. Liver failure. Hallucinations. Suicidal thoughts. And, delivered with the same tone one might use to announce a bake sale, death (the ultimate side effect).

But the viewer doesn’t notice. Because at that exact moment, a corgi puppy trots across the screen with that self-important waddle only corgis possess. The couple in the meadow keeps smiling. The kayak glides across the lake. The golden retriever looks spiritually fulfilled.

The message is unmistakable: Ignore the mortality warning. Look at the puppy.

This is not accidental. It is emotional misdirection engineered with the precision of a stage illusion.

The inversion of the clinical sequence

In medicine, the traditional order is simple: Symptom → Evaluation → Diagnosis → Treatment. In the era of direct-to-consumer advertising, the sequence has been quietly reversed: Commercial → Desire → Request → MD as speed bump.

By the time the patient walks into the exam room, the drug has already won the psychological battle. They’ve seen the lifestyle fantasy. They’ve rehearsed the request. They’ve internalized the promise.

The physician is no longer the first opinion. We are the second, and often too late to prevent harm.

I’ve had patients arrive with a diagnosis already in hand, courtesy of a 30-second commercial featuring a corgi, a meadow, and a sunset. The clinical encounter becomes less about evaluating symptoms and more about negotiating with a marketing campaign.

The corgi as placebo

Years ago, I used to do a riff for parents about placebo: “Placebo is Latin for ‘I shall please.’ The side effects are Latin for ‘I shall ruin your weekend.'” In pharmaceutical advertising, the corgi is the placebo. The side effects are the part that ruins your weekend.

The corgi is adorable, distracting, and completely irrelevant to the medical decision. But it works. It softens the warning. It neutralizes the danger. It keeps the viewer emotionally warm while the voiceover lists complications that would make a toxicologist sweat.

The corgi is there to make you forget the fine print. The MD is there to deal with the fine print once it becomes reality.

The absurd escalation: from mild eczema to mortality

The escalation is always disproportionate:

• Mild eczema
• Catastrophic side effects
• A corgi puppy trotting through a meadow as if nothing is happening

It’s a joke with a punchline no one hears until they’re sitting in an exam room asking why their liver enzymes are climbing. The ads rely on a simple psychological truth: People remember the imagery, not the warnings. They remember the puppy, not the pancreatitis.

When do patients actually see an MD?

Not before the commercial. Not before the request. Not before the prescription is imagined.

They see us after:

• The rash worsens.
• The dizziness becomes falls.
• The “rare but serious” event stops being rare.
• The liver enzymes rise.
• The mood shifts.
• The side effects have already started.

The clinical encounter begins only after the commercial ends. And sometimes, only after the consequences begin.

The shoulder-replacement epiphany

Somewhere between the ice machine cycles and the physical therapy sessions, I realized that my own surgical consent forms (the ones listing every complication up to and including death) were at least honest. They didn’t hide behind puppies. They didn’t pair mortality with a sunset. They didn’t try to soften the blow with a corgi.

They simply stated the truth: Medicine carries risk. Real risk. Risk that deserves clarity, not choreography.

If direct-to-consumer ads were held to the same standard, the corgi would be replaced by a clinician explaining the actual likelihood of the side effects being described. The kayak would be replaced by a conversation. The meadow would be replaced by informed consent.

But that wouldn’t sell the drug.

The real fine print

The fine print isn’t fine. It’s the real medicine. It’s the part that matters. And it’s the part no one hears until they’re sitting in the exam room asking why the treatment for mild eczema came with a warning label that included mortality.

Direct-to-consumer advertising has replaced the first medical opinion with a marketing campaign. Physicians are left to manage the consequences.

And no corgi, no matter how charming, can distract from that.

Ronald L. Lindsay is a retired developmental-behavioral pediatrician whose career spanned military medicine, academic leadership, and national advocacy for dignity-centered neurodevelopmental care. His NIH-funded work with the RUPP Autism Network helped define evidence-based approaches to autism and related developmental disorders.

He directed the LEND Program at The Ohio State University and founded JBLM CARES, a $10 million autism resource center for military families. His writing spans clinical scholarship and long-form fiction. He is the author of The Mercy Directive and the six-novel Cassandra series, a completed political and medical fiction saga tracing the rise of the Cassandra system from its origins to its national and international legacy. His forthcoming memoir, The Quiet Architect, examines how conscience and structure collide in modern medicine.

He shares updates on LinkedIn.